Association of interleukin-6 and C-reactive protein genetic polymorphisms levels with venous thromboembolism

Chinese Medical Journal

Volumn 125, Issue 22, 2012, Pages 3997-4002

  Mahemuti, Ailiman ^a   Abudureheman, Kailibinuer ^a   Aihemaiti, Xiaimuxikamaier ^a   Hu, Xue Mei ^a   Xia, Yu Ning ^a   Tang, Bao Peng ^a   Upur, Halmurat ^a  

^a XINJIANG MEDICAL UNIVERSITY   (China)

Author keywords

C reactive protein; Gene polymorphism; Interleukin 6; Venous thromboembolism

Indexed keywords

C REACTIVE PROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INTERLEUKIN 6;

ADULT; ALLELE; ARTICLE; BODY MASS; CONTROLLED STUDY; DNA POLYMORPHISM; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENOTYPE; HOMOZYGOSITY; HUMAN; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PROMOTER REGION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RISK FACTOR; VENOUS THROMBOEMBOLISM;

ADULT; AGED; C-REACTIVE PROTEIN; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INTERLEUKIN-6; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; VENOUS THROMBOEMBOLISM;

EID: 84872351061     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0366-6999.2012.22.016     Document Type: Article

References (43)

1. Manly DA, Boles J, Mackman N. Role of tissue factor in venous thrombosis. Annu Rev Physiol 2011; 73: 515-525.
2. Deguchi H, Pecheniuk NM, Elias DJ, Averell PM, Griffin JH. High-density lipoprotein deficiency and dyslipoproteinemia associated with venous thrombosis in men. Circulation 2005; 112: 893-899.
3. Tsai AW, Cushman M, Rosamond WD, Heckbert SR, Polak JF, Folsom AR. Cardiovascular risk factors and venous thromboembolism incidence: the longitudinal investigation of thromboembolism etiology. Arch Intern Med 2002; 162: 1182-1189.
4. Holst AG, Jensen G, Prescott E. Risk factors for venous thromboembolism: results from the Copenhagen City Heart Study. Circulation 2010; 121: 1896-1903.
5. Yoo HH, De Paiva SA, Silveira LV, Queluz TT. Logistic regression analysis of potential prognostic factors for pulmonary thromboembolism. Chest 2003; 123: 813-821.
6. Prandoni P, Bilora F, Marchiori A, Bernardi E, Petrobelli F, Lensing AW, et al. An association between atherosclerosis and venous thrombosis. N Engl J Med 2003; 348: 1435-1441.
7. Ageno W, Becattini C, Brighton T, Selby R, Kamphuisen PW. Cardiovascular risk factors and venous thromboembolism: a meta-analysis. Circulation 2008; 117: 93-102.
8. Beckers MM, Ruven HJ, Haas FJ, Doevendans PA, ten Cate H, Prins MH, et al. Single nucleotide polymorphisms in inflammation-related genes are associated with venous thromboembolism. Eur J Intern Med 2010; 21: 289-292.
9. Zacho J, Tybjaerg-Hansen A, Nordestgaard B G. C-reactive protein and risk of venous thromboembolism in the general population. Arterioscler Thromb Vasc Biol 2010; 30: 1672-1678.
10. Dai DF, Chiang FT, Lin JL, Huang LY, Chen CL, Chang CJ, et al. Human C-reactive protein (CRP) gene 1059G>C polymorphism is associated with plasma CRP concentration in patients receiving coronary angiography. J Formos Med Assoc 2007; 106: 347-354.
11. van Aken BE, den Heijer M, Bos GM, van Deventer SJ, Reitsma PH. Recurrent venous thrombosis and markers of inflammation. Thromb Haemost 2000; 83: 536-539.
12. Zee RY, Glynn RJ, Cheng S, Steiner L, Rose L, Ridker PM. An evaluation of candidate genes of inflammation and thrombosis in relation to the risk of venous thromboembolism: the Women's Genome Health Study. Circ Cardiovasc Genet 2009; 2: 57-62.
13. Pai JK, Mukamal KJ, Rexrode KM, Rimm EB. C-reactive protein (CRP) gene polymorphisms, CRP levels and risk of incident coronary heart disease in two nested case-control studies. PLoS One 2008; 3: e1395.
14. Torbicki A, Perrier A, Konstantinides S. Guidelines on the diagnosis and management of acute pulmonary embolism: the Task Force for the Diagnosis and Management of Acute pulmonary Embolism of the European Society of Cardiology (ESC). Eur Heart J 2008; 29: 2276-2315.
15. Anogeianaki A, Angelucci D, Cianchetti E, D'alessandro M, Maccauro G, Saggini A, et al. Atherosclerosis: a classic inflammatory disease. Int J Immunopathol Pharmacol 2011; 24: 817-825.
16. Zee RY, Hegener HH, Cook NR, Ridker PM. C-reactive protein gene polymorphisms and the risk of venous thromboembolism: a haplotype-based analysis. J Thromb Haemost 2004; 2: 1240-1243.
17. Matos MF, Lourenço DM, Orikaza CM, Bajerl JA, Noguti MA, Morelli VM. The role of IL-6, IL-8 and MCP-1 and their promoter polymorphisms IL-6 -174GC, IL-8 -251AT and MCP-1 -2518AG in the risk of venous thromboembolism: a case-control study. Thromb Res 2011; 128: 216-220.
18. Christiansen SC, Naess IA, Cannegieter SC, Hammerstrøm J, Rosendaal FR, Reitsma PH. Inflammatory cytokines as risk factors for a first venous thrombosis: a prospective population-based study. PLoS Med 2006; 3: e334.
19. Tsai AW, Cushman M, Rosamond WD, Heckbert SR, Tracy R P, Aleksic N, et al. Coagulation factors, inflammation markers, and venous thromboembolism: the longitudinal investigation of thromboembolism etiology (LITE). Am J Med 2002; 113: 636-642.
20. Folsom AR, Lutsey PL, Astor BC, Cushman M. C-reactive protein and venous thromboembolism. A prospective investigation in the ARIC cohort. Thromb Haemost 2009; 102: 615-619.
21. Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA 2001; 286: 327-334.
22. Bamoulid J, Courivaud C, Deschamps M, Gaugler B, Tiberghien P, Chalopin JM, et al. The interleukin-6 gene promoter polymorphism -174 and atherosclerotic events in overweight transplanted patients. J Transplant 2011; 2011: 803429.
23. Kamphuisen PW, Eikenboom JC, Vos HL, Pablo R, Sturk A, Bertina RM, et al. Increased levels of factor VIII and fibrinogen in patients with venous thrombosis are not caused by acute phase reactions. Thromb Haemost 1999; 81: 680-683.
24. Reitsma PH, Rosendaal FR. Activation of innate immunity in patients with venous thrombosis: the Leiden Thrombophilia Study. J Thromb Haemost 2004; 2: 619-622.
25. Rose-John S, Waetzig GH, Scheller J, Grotzinger J, Seegert D. The IL-6/sIL-6R complex as a novel target for therapeutic approaches. Expert Opin Ther Targets 2007; 11: 613-624.
26. Cermak J, Key NS, Bach RR, Balla J, Jacob HS, Vercellotti GM. C-reactive protein induces human peripheral blood monocytes to synthesize tissue factor. Blood 1993; 82: 513-520.
27. Wang MF, Yang LH, Yang XL, Zhang RJ, Dong CX, Hou LH, et al. 1059 g/c gene polymorphism of C-reactive protein in patients with deep vein thrombosis. J Exp Hematol (Chin) 2011; 19: 769-771.
28. Zee RY, Ridker PM. Polymorphism in the human C-reactive protein (CRP) gene, plasma concentrations of CRP, and the risk of future arterial thrombosis. Atherosclerosis 2002; 162: 217-219.
29. Brull DJ, Serrano N, Zito F, Jones L, Montgomery HE, Rumley A, et al. Human CRP gene polymorphism influences CRP levels: implications for the prediction and pathogenesis of coronary heart disease. Arterioscler Thromb Vasc Biol 2003; 23: 2063-2069.
30. Reitsma PH, Rosendaal FR. Activation of innate immunity in patients with venous thrombosis: the Leiden Thrombophilia Study. J Thromb Haemost 2004; 2: 619-622.
31. Mälarstig A, Wallentin L, Siegbahn A. Genetic variation in the interleukin-6 gene in relation to risk and outcomes in acute coronary syndrome. Thromb Res 2007; 119: 467-473.
32. Burstein SA, Peng J, Friese P, Wolf RF, Harrison P, Downs T, et al. Cytokine-induced alteration of platelet and hemostatic function. Stem Cells 1996; 14: 154-162.
33. Downing LJ, Strieter RM, Kadell AM, Wilke CA, Austin JC, Hare BD, et al. IL-10 regulates thrombus-induced vein wall inflammation and thrombosis. J Immunol 1998; 161: 1471-1476.
34. Wakefield TW, Strieter RM, Prince MR, Downing LJ, Greenfield LJ. Pathogenesis of venous thrombosis: a new insight. Cardiovasc Surg 1997; 5: 6-15.
35. Moheimani F, Jackson DE. Venous thromboembolism: classification, risk factors, diagnosis, and management. ISRN Hematol 2011; 2011: 124610.
36. Vayá A, Mira Y, Ferrando F, Contreras M, Estelles A, España F, et al. Hyperlipidaemia and venous thromboembolism in patients lacking thrombophilic risk factors. Br J Haematol 2002; 118: 255-259.
37. Eichinger S, Pecheniuk NM, Hron G, Deguchi H, Schemper M, Kyrle PA, et al. High-density lipoprotein and the risk of recurrent venous thromboembolism. Circulation 2007; 115: 1609-1614.
38. Griffin JH, Kojima K, Banka CL, Curtiss LK, Fernandez JA. High-density lipoprotein enhancement of anticoagulant activities of plasma protein S and activated protein C. J Clin Invest 1999; 103: 219-227.
39. Mineo C, Deguchi H, Griffin JH, Shaul PW. Endothelial and antithrombotic actions of HDL-C. Circ Res 2006; 98: 1352-1364.
40. Levi M, van der Poll T, Buller HR. Bidirectional relation between inflammation and coagulation. Circulation 2004; 109: 2698-2704.
41. Eichinger S, Hron G, Bialonczyk C, Hirschl M, Minar E, Wagner O, et al. Overweight, obesity and the risk of recurrent venous thromboembolism. Arch Intern Med 2008; 168: 1678-1683.
42. Craft MK, Reed MJ. Venous thromboembolic disease and hematologic considerations in obesity. Crit Care Clin 2010; 26: 637-640.
43. Darvall KA, Sam RC, Silverman SH, Bradbury AW, Adam DJ. Obesity and thrombosis. Eur J Vasc Endovasc Surg 2007;